Last reviewed · How we verify

NCT06655220

A Study in Healthy Men to Test Whether BI 1815368 Influences the Amount of Metformin in the Body

Completed Phase 1 Last updated 5 March 2025
What this trial tests

Phase 1 trial testing Metformin hydrochloride in Healthy in 14 participants. Completed in 13 January 2025.

Timeline
8 November 2024
Primary endpoint
8 December 2024
13 January 2025

Quick facts

Lead sponsorBoehringer Ingelheim
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment14
Start date8 November 2024
Primary completion8 December 2024
Estimated completion13 January 2025
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

Adults 18 to 50, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this trial is to investigate the effect on the exposure of metformin in plasma when administered as an oral multiple dose together with multiple oral doses of BI 1815368 (Test, T) as compared to when metformin is administered as an oral multiple dose alone (Reference, R).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Metformin hydrochloride

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Boehringer Ingelheim trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06655220.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing